Multicenter Registry Study Of Cerebral Venous Thrombosis In China (RETAIN-CH)
A Registry Study of Cerebral Venous Sinus Thrombosis in China
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100069
- Xuan Wu Hospital,Capital Medical University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Cerebral venous sinus thrombosis, deep cerebral vein thrombosis and cortical vein thrombosis diagnosed by digital subtraction angiography (DSA), magnetic resonance venography (MRV), computed tomography venography (CTV) or high-resolution magnetic resonance imaging (HR-MRI).
Exclusion Criteria:
- None of the patient, trustee or immediate family members signed the informed consent.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Favorable clinical outcome (modified Rankin score 0-1)
Time Frame: Baseline to three years
|
Baseline to three years
|
|
|
All-cause mortality
Time Frame: Baseline to three years
|
A combination of death form of all causes
|
Baseline to three years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Recurrence of cerebral venous thrombosis
Time Frame: Baseline to three years
|
Diagnosed by DSA, MRV, CTV or HR-MRI
|
Baseline to three years
|
|
Favorable clinical outcome (modified Rankin score 0-2)
Time Frame: Baseline to three years
|
Baseline to three years
|
|
|
Headache after CVT
Time Frame: Baseline to three years
|
Headache Impact Test - 6 score
|
Baseline to three years
|
|
Incidence of hemorrhagic complication
Time Frame: Baseline to three years
|
Extracranial hemorrhage (fall in hemoglobin of 2 gram/dl or more within 48 hours) or intracranial hemorrhage
|
Baseline to three years
|
|
Recanalization rate of cerebral venous system
Time Frame: Baseline to three years
|
Baseline to three years
|
|
|
Incidence of epilepsy
Time Frame: Baseline to three years
|
Baseline to three years
|
|
|
Incidence of acute ischemic stroke
Time Frame: Baseline to three years
|
Baseline to three years
|
|
|
Incidence of pulmonary embolism
Time Frame: Baseline to three years
|
Baseline to three years
|
|
|
Psychological distress after CVT
Time Frame: Baseline to three years
|
Population Health Questionnaire (PHQ)-9 score
|
Baseline to three years
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- RETAIN-CH
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.